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Objectives: To describe prenatal patterns of antidepressant use and their relationship to
depression in pregnancy.Methods: A total of 276 high risk women completed a structured clinical
interview to investigate use of antidepressant medication. Results: Of the women interviewed,
13% (n=36) reported current use of antidepressant medication; there were no differences in
depression or health functioning outcomes between women taking antidepressants and those not
using them. Conclusions: Monitoring the depressive symptoms of women using pharmacotherapy
during pregnancy is important to optimize their treatment.







Major depressive disorder (MDD) and elevated depressive
symptoms are common in pregnancy [1] and both have been
linked to pregnancy and birth complications, as well as poor
neonatal outcomes. In one study, the investigators found a
significantly higher risk of low and very low birth weight and
preterm neonates in women with a psychiatric diagnosis [2].
Other studies have linked prenatal depression to elevated
fetal activity and delayed prenatal growth [3], and postnatal
depression to adverse neonatal outcomes [4,5]. Recent re-
ports have also suggested that treatments for depression
around the time of pregnancy are underutilized [6]. Moreover,of Psychiatry, University of
th Road Box 5766, Ann Arbor,
fax: +1 734 9368907.
edu (S.M. Marcus).
007 International Federation ofCohen et al. [7] showed that up to 80% of women may relapse
when their medication is discontinued during pregnancy.
There is a great deal of controversy in the literature re-
garding the use of antidepressants during pregnancy. The
majority of early studies examining the use of antidepressants
during pregnancy suggest that the tricyclic antidepressants
and selective serotonin reuptake inhibitors (SSRIs) are unlikely
to contribute to major congenital anomalies above the base-
line risk of 1%–3% seen in the general population [8–13].
However, some studies do suggest that first trimester expo-
sure to SSRIs may contribute to preterm delivery, restricted
fetal growth, and minor malformations [14–16]. Additionally,
there have been several reports suggesting that prenatal
exposure to SSRIsmay be associatedwith neonatalwithdrawal
including irritability, increased tone, increased crying, and
sleep and appetite dysregulation [17]. A recent report by
GlaxoSmithKline [18] suggesting that infants exposed to
paroxetine during the first trimester had an increased risk
of congenital malformations (4% vs 2% in the generalGynecology and Obstetrics. Published by Elsevier Ireland Ltd.
Table 1 Antidepressant medication use reported during
pregnancy: mean dosage and duration of use (n=36)a
Drug name No.b Dosage, mg Duration of use
in months
Fluoxetine 12 23.3 (10–40) 18 (1–108)
Sertraline 8 68.7 (50–100) 10.2 (1–48)
Paroxetine 5 30 (10–60) 11 (b1–24)
Bupropion 3 166.6 (100–200) 14.5 (b1–36)
Citalopram 3 20 (– –) 4 (3–5)
Venlafaxine 1 175 (– –) 20 (– –)
aValues are given as mean (range).
bThe number reported in the table is lower than the total number
of women reporting antidepressant use due to missing dosage
information.
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the general population), resulted in the reclassification of
paroxetine as a category D agent during pregnancy. Finally,
Chambers et al. [14] suggest that persistent pulmonary
hypertension of the newborn may be associated with late
trimester use of SSRIs. In these studies therewas no control for
maternal illness or symptom severity. As such, the relative
contribution of undertreated maternal depressive symptoms
and illness severity with use of SSRIs was not examined. Only
one study compared control (depression plus no fluoxetine)
and treated (depression plus fluoxetine) and found no effect
of fluoxetine exposure on birth weight, gestational age, or
Neonatal Intensive Care Unit (NICU) admissions [19].
The purpose of the present study was to describe the rates
and patterns of the use of common antidepressants during
pregnancy, and to examine the relationship of different
usage patterns of antidepressants to depressive symptoms
and health functioning in a cohort of depressed, pregnant
women identified in obstetrics settings.
2. Methods
As part of a larger pregnancy screening project, women were
screened for depressive symptoms (mean 24±10.4 gestational
weeks) when seeking prenatal care at 5 University of Michigan
affiliated obstetrics clinics. The clinics serve patients with
managed care insurance plans (70.6%), Medicare (7.9%), Me-
dicaid (14.4%), and no or unknown insurance (7.1%). The mean
age of participants was 28.6±6 years. Most were married (74%);
others had a live-in partner (10%), were separated (1.3%),
divorced (1.8%), widowed (0.1%), or never married (12.8%). The
racial distribution of the sample reflected that of southeast
lower Michigan as follows: 73% white, 13% African American,
9.3% Asian, 2.4% Hispanic, 0.7% Native American, and 1.6% other
race. Full details about screening procedures have been
described in detail elsewhere [6]. A total of 276 (16% of those
screened) women were eligible and completed prenatal inter-
views based on a Center for Epidemiologic Studies Depression
Scale (CES-D) score of 16 or greater, self-reported major
depression in the past 6 months, or discontinuation of anti-
depressant medications due to conception. Confidentiality was
maintained, informed consent obtained, and all study procedures
were approved by the Institutional Review Board of the University
of Michigan Medical School.
Depressive symptomatology was measured using the Center
for Epidemiological Studies Depression Scale (CES-D). The CES-D
is used widely as a depression screening instrument in
nonclinical populations, with good correlation with the Beck
Depression Inventory (r=0.87) [20]. The standard cutoff score of
16 was used to determine significantly elevated depressive
symptomatology. The Structured Clinical Interview for DSM-IV
(SCID) interview was administered to assess presence and
severity of current and past psychiatric disorders. As reported
previously [6], 17% (46/276) of the sample met criteria for
current MDD based on SCID interview, and an additional 23% met
criteria for a past history of MDD (n=63). The Beck Depression
Inventory-II was also administered as a repeated measure to
assess severity of symptoms of depression. Health Functioning
was assessed using the Medical Outcome Study (MOS) Short Form
Survey (SF-36) [21], which has been used as an indicator of
functional status changes during pregnancy [4,5], and measures
8 domains: general health, physical functioning, physical rolefunctioning, bodily pain, vitality, mental health, emotional role
functioning, and social functioning.
Data analysis first described rates of antidepressant medi-
cation use among the sample. Mean differences on BDI-II and SF-
36 scores were examined using t test, with P=0.05 considered
statistically significant. Means, standard deviations, and ranges
of each antidepressant medication dosage were also computed.
3. Results
Of all women completing the prenatal interview, 13% (n=36)
reported current use of antidepressant medication. As pre-
viously reported [6], an additional 16 (6%) were receiving any
other form of treatment, and a minority of women who met
criteria for current MDD (19%, n=9) were taking antidepres-
sant medication. No differences were found in rates of
medication use between MDD and the rest of the sample
(i.e., women with risk for depression as defined above but no
current MDD). As assessed during pregnancy, no significant
differences in BDI-II scores or SF-36 health functioning in-
dices were found between women with MDD currently taking
antidepressants and those not taking antidepressants (mean
BDI-II with medications 24.9±7.4 vs mean BDI-II without
medication 28.1±9.1). Similarly, when examining the total
high risk sample (regardless of MDD status), no differences
between women taking antidepressants and those not taking
medications were found on BDI-II scores (no antidepressants
mean 16.1±9.4 vs taking antidepressants mean 18.9±9.4).
No differences between women taking and not taking anti-
depressants were found in the any of the SF-36 scales, with
the exception of emotional role functioning. Women using
antidepressants showed significantly worse emotional role
functioning (which indicates the extent to which work and
other important activities were impacted by psychiatric
symptoms) than those not taking antidepressants (t [1, 273]=
4.1, Pb0.05).
Given that antidepressant medication use was not asso-
ciated with symptom differences compared with the non-
medicated group, we were interested in the duration and
dosage of the medications used by women in our sample, as
well as the consistency of use. Table 1 shows the mean dos-
age, duration of use, as well as the ranges of each reported
antidepressant medication. Among the interviewed sample
of womenwho reported any antidepressant medication use in
250 S.M. Marcus, H.A. Flynnthe 2 years prior to pregnancy, 3 categories regarding
continuity of use emerged: 1 group who reported discon-
tinuing use of antidepressants as a result of pregnancy (41%),
1 group who reported discontinuing use due to pregnancy and
then resumed use at some point during pregnancy (21%), and
1 group that continued antidepressant use into pregnancy
(38%). No significant differences in mean BDI-II scores or
SF-36 health functioning indices were found among the 3
groups, but all 3 groups showed mean elevated BDI-II scores
(18.7±11; 21.5±9.4; 17.7±9.5, respectively).4. Discussion
The present study compared depression and health function-
ing measures in pregnant women recruited from obstetrics
settings taking antidepressant medication with women not
taking antidepressants. The study found that the majority of
women using antidepressant medication continued to
experience mood symptoms despite their use, suggesting
suboptimal treatment. The present study adds to our pre-
vious work in this area by examining depressive symptoma-
tology (as measured by the BDI-II) and health functioning in
women with and without a SCID diagnosis of MDD using anti-
depressant medication during pregnancy, as well as detailed
information on dosing and duration of treatment within this
symptomatic group based on interview data. The findings are
similar to those reported in a previous screening study [22] in
which women using and not using antidepressant medication
showed similar elevations in CES-D scores. However, that
previous cohort of women was comprised of a general pre-
natal care seeking sample, and information on MDD status
and on dosing and duration of medication treatment was not
obtained.
The group of women investigated in this study was a high
risk sample for depression, with 17% meeting current criteria
for MDD by diagnostic interview and an additional 24% for
past history of MDD, the strongest risk factor for subsequent
depression. The majority of women studied continued to
show elevated mood symptoms as measured by the BDI-II
during their pregnancy and there were no differences in
symptom severity or of health functioning between those
taking medication compared with women not taking medica-
tion. Although most women reported daily use for at least
8 weeks, the mean dosage of both venlafaxine and bupropion
was below the dosage that commonly permits full remission
of symptoms. Likewise in clinical practice, SSRI doses
frequently exceed the mean dosage of fluoxetine, paro-
xetine and citalopram observed in this study. Furthermore,
studies with the tricyclic antidepressants revealed that as
maternal plasma volumes increased, antidepressant blood
levels fall with consequent re-emergence of mood symptoms
during later pregnancy [23,24]. While there are no published
data on optimal antidepressant dosing during pregnancy and
no studies specifically discussing efficacy of antidepressants
during pregnancy, the American Psychiatric Association Treat-
ment Recommendations for Patients with Major Depressive
Disorder recommends the following daily dosages: 20–60 mg
of citalopram, 20–80 mg of fluoxetine, 20–60 mg of paroxe-
tine, 150–450 mg of bupropion, and 150–375 mg of venlafa-
xine. Among these women (n=254), 70% reported some form
of counseling or therapy.The service implications for these findings are consider-
able and suggest that women merit much closer monitoring
for depressive symptoms during pregnancy. In our sample,
most women were not treated, and many remained
symptomatic despite use of pharmacotherapy. It is critical
that physicians treating pregnant women monitor symp-
toms so that women can be properly referred for
treatment when indicated and pharmacotherapy can be
optimized when women remain symptomatic. Many studies
[25] document improvement in cognitive outcomes of
infants when their mothers are treated for depression in
pregnancy.
One important methodological consideration of this study
was that only women who reported some risk of depression
(primarily defined as elevated score on the depression
screening measure) were included in the study. Therefore,
we may not have captured asymptomatic women taking
antidepressants. Recruitment analyses showed that only 11%
of women who had been taking antidepressants in the 2-year
period prior to screening were not eligible to be interviewed
based on our depression risk criteria, suggesting that the
majority (89%) of all users of antidepressants were captured
in this study. Nonetheless, future studies should compare
depression outcomes among medication use groups unse-
lected for depression risk. Another limitation of the study is
that, although women reported dosage, duration and daily
use of the medications, adherence and pharmacy data were
not obtained. It is noted that a randomized controlled trial
would be necessary to fully study the effectiveness of medi-
cations during pregnancy, however, most internal review
boards disallow such trials using antidepressant medication
during pregnancy. Moreover, it is acknowledged that depres-
sive symptomatology may have been impacted by virtue of
study participation.
For both pregnant and nonpregnant women alike, remis-
sion of symptoms is the goal. Simultaneous exposure to both
medication and symptoms of depression during pregnancy
may put the fetus at unnecessary risk. Furthermore, current
studies exploring the relative risk of pharmacotherapy during
pregnancy may be reporting on both the risks of pharma-
cotherapy and undertreated depression, if the sample
population is similar to this community sample. It under-
scores the clinical importance of monitoring mood symptoms
when using pharmacotherapy during pregnancy and its
consideration when reporting the potential medication
effects on the neonate.
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